Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study
详细信息 查看全文
- 作者：Laure Peyro Saint Paula ; ; Christian Creveuila ; Olivier Heinzlefb ; Jerome De Sezec ; Patrick Vermerschd ; Giovanni Castelnovoe ; Philippe Cabref ; Marc Debouverieg ; Bruno Brocheth ; Benoit Dupuyi ; Pierre Lebiezi ; É ; ric Sartorij ; Pierre Clavelouk ; David Brassatl ; Christine Lebrun-Frenaym ; David Daplaudn ; Jean Pelletiero ; Irè ; ne Comanp ; Patrick Hautecoeurq ; Ayman Tourbahr ; Gilles Defers ; t
- 关键词：Memantine ; Multiple sclerosis ; Cognitive disorders ; Patient safety ; Clinical trial ; Randomized ; Placebo-controlled ; PASAT ; Cognitive impairment ; Test of Attentional Performance
- 刊名：Journal of the Neurological Sciences
- 出版年：2016
- 出版时间：15 April 2016
- 年：2016
- 卷：363
- 期：Complete
- 页码：69-76
- 全文大小：476 K
文摘
- •
Cognitive impairment is frequently observed in multiple sclerosis (MS).
- •
There is currently no drug therapy to improve cognitive impairment.
- •
This study suggests that memantine is not effective after 52 weeks but power was decreased due to high discontinuation rate.
- •
The safety profile of memantine from this trial was less favorable than that established on the basis of dementia trials.